Viewing Study NCT06154902



Ignite Creation Date: 2024-05-06 @ 7:50 PM
Last Modification Date: 2024-10-26 @ 3:15 PM
Study NCT ID: NCT06154902
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2023-12-04
First Post: 2023-11-27

Brief Title: Real-World Outcomes in RelapsedRefractory Multiple Myeloma Patients Treated or Eligible for Treatment With Idecabtagene Vicleucel
Sponsor: Bristol-Myers Squibb
Organization: Bristol-Myers Squibb

Study Overview

Official Title: ABE-DESCART Study Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma Idecabtagene Vicleucel in Real World Setting in France A Database Analysis Based on the DESCAR-T Registry
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2023-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ABE-DESCART
Brief Summary: The purpose of this study is to describe demographic and disease characteristics treatment patterns and clinical outcomes in the real-world setting among participants in France with relapsedrefractory multiple myeloma RRMM who are eligible for treatment with or have been treated with idecabtagene vicleucel This study will use both prospective and retrospective data from the DESCAR-T registry database
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None